Tadocizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C2107H3252N562O673S12 |
| Molar mass | 47609.17 g·mol−1 |
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It is used in the treatment of patients undergoing percutaneous coronary interventions.[1]
This drug was developed by Yamanōchi Pharma America, Inc.
References
- ^ STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - TADOCIZUMAB, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |